IP Library Granted Patent US 10,577,337
Granted Patent B2
US 10,577,337 · App. 16/420,669 · Granted Mar 3, 2020

Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof

Inventors: Jean-Francois Rossignol (St. Petersburg, FL); Andrew Stachulski (Tampa, FL)
Assignee: Romark Laboratories, L.C.
C07D277/58A61K9/20A61K9/48A61K31/138A61K31/426A61K31/506A61K31/555A61K31/704A61K31/7068A61K45/06A61P31/04A61P31/12A61P35/00C07D277/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,577,337
App. No.
16/420,669
Granted
Mar 3, 2020
Kind
B2
Abstract

Prodrugs of tizoxanide, an analogue or salt thereof are disclosed. The prodrugs have an ester moiety comprising an amino acid moiety, and increase the bioavailability of the tizoxanide, an analogue or salt thereof. Compositions and methods of treating an intracellular protozoan infection, a viral infection or a cancer are also disclosed.

Claims (12)

1. A compound having formula:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutically acceptable salt of the compound of claim 1 .

3. The salt of claim 2 , which is a hydrochloric salt.

4. A pharmaceutical composition comprising the compound of claim 1 or its pharmaceutically acceptable salt.

5. The pharmaceutical composition of claim 4 , wherein the composition is an injectable formulation.

6. The pharmaceutical composition of claim 4 , wherein the composition is an intravenous formulation.

7. The pharmaceutical composition of claim 5 , comprising an aqueous solution of the compound or its pharmaceutically acceptable salt.

8. The pharmaceutical composition of claim 4 in a dosage form suitable for injection.

9. The pharmaceutical composition of claim 8 , wherein the dosage form is suitable for intravenous administration.

10. The pharmaceutical composition of claim 4 , wherein the composition is an oral formulation.

11. A pharmaceutical formulation comprising an aqueous solution of the compound of claim 1 or its pharmaceutically acceptable salt.

Assignments (1)
SECURITY INTEREST Recorded Nov 16, 2019
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 051030/0613 →